Duoskin

Form: Creme
Dosage: 15g
Packaging: Tube 15 g

Active substance:   Isoconazole – Diflucortolone

Form : Hydrophilic Cream for skin application (excellent penetration in the skin)

Dosage : Each gram of cream contains 10 mg isoconazole nitrate and 1 mg diflucortolone valerate.

Packaging :  Box with 1 tube of cream (15 g of cream)

Target : adults, adolescents  et children

Initial or interim treatment of superficial fungal infections of the skin which are accompanied by highly inflammatory (redness -swelling – pain – burning sensation) or eczematous skin conditions, e.g. in the region of the hands, the interdigital spaces of the feet and in the inguinal and genital regions.

Duoskin should be applied twice daily to the diseased areas of skin.

To treat the affected interdigital spaces in the fingers and toes, it is often recommended to apply a gauze compress coated with Duoskin between the fingers or toes.

Treatment with Duoskin must be terminated after regression of the inflammatory or eczematous skin conditions or at the latest after 2 weeks.

The combination of the antifungal with the corticosteroid reinforces the action and will make the inflammatory symptoms disappear faster. In order to obtain a complete cure it is necessary to continue the antifungal treatment until the mycosis is eradicated.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma